Furthermore, it has been confirmed that Delta-like 1 (DLL1) could promote immunotherapy of BRCA by regulating CD8+ T cells to keep TME in a normal state for a long time (Zhang et al., 2021); CD2 expression is related to a variety of tumor-infiltrating immune cells and serves as an immune-associated prognostic biomarker to regulate the TME of BRCA (Chen Y. et al., 2021); ATP2C2 could maintain the immune dominance of TME, which might serve as a prognostic marker for BRCA patients and provide a potential target for the treatment of BRCA (Liu J. et al., 2021). This evidence concerns the gene CD8A and neoplasm.